The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $249,810 to Yuma Therapeutics Corporation (Yuma) to develop small molecules to treat Alzheimer's disease.
The award will fund work to develop Yuma's innovative disease-modifying pharmaceutical compounds that target neurofibrillary tangles resulting from abnormal forms of the protein tau, which represents a promising new approach with potential to affect disease progression in Alzheimer's disease.
"We are excited to support Yuma Therapeutics innovative program in this area," said Howard Fillit, M.D., executive director of the ADDF. "Small molecule therapeutics targeting the tau pathway could result in a disease-modifying therapy for Alzheimer's disease."
"We are honored to be selected for this peer-reviewed grant, which recognizes the promise of Yuma's approach to generating novel Alzheimer's disease therapies," said Yukari Y. Perrella, founder and president of Yuma. "We look forward to interacting with the ADDF team."
How cohesin mechanics and nanotracker tech are redefining DNA research